**PATENT** 

Attorney Docket No. 213721

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Feussner et al.

Group Art Unit: Unassigned

Application No. Unassigned (U.S. National Phase of PCT/EP00/02545)

Examiner: Unassigned

Filed: September 28, 2001

For: LINOLEATE- AND LINOLENATE-

LIPOXYGENASE MUTANTS

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

 $\boxtimes$ within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under -37-CFR-1-53(d); (b)-within-three-months-of-the-date-of-entry-of-the-national-stage-asset forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes one of: the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below). orthe fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below). after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed. Copies of the References Copies of the references listed on the enclosed Form 1449 are enclosed herewith.  $\boxtimes$ Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). Copies of two foreign search reports are enclosed herewith.  $\boxtimes$ The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

In re Appln. of Feussner et al.

Application No. Unassigned (U.S. National Phase of PCT/EP00/02545)

In re Appln. of Feussner et al. Application No. Unassigned (U.S. National Phase of PCT/EP00/02545)

		Q 1 0 7 0 7 0				
	U.S. APPLIC		Status (check one)			
h	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
2.						
3.					_	
<u>J.</u>			<u> </u>		L	
Stater	ment under 37 CFR	1.97(e)				
	Information Disclo	hereby states that each sure Statement was fince in a counterpart foreign filing of the Information	irst cited in a ign patent appl	ny commun lication not i	ication from a	
	Information Discloration office in a counter undersigned after n Information Discloration	hereby states that no sure Statement was cited erpart foreign patent ap- naking reasonable inqui- osure Statement was ore than three months int.	I in a communication, and ry, no item of iknown to any	cation from to the known information of individual	a foreign patent owledge of the contained in the designated in	
Stater	nent under 37 CFR	1.704(d)				
	The <b>undersigned</b> hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.					
Fees						
$\boxtimes$	No fee is owed by t The IDS Fee of \$18	he applicant(s). 30 under 37 CFR 1.17(p)	) is enclosed he	erewith.		
Metho	od of Payment of Fe	es				
	Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$ this communication is enclosed for that purpose.)  (A duplicate copy of					
Autho	orization to Charge	Additional Fees				

3

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed

 $\boxtimes$ 

for that purpose.)

09/937908

JC05 Rec'd PCT/PTO 2 8 SEP 2001

In re Appln. of Feussner et al.

Application No. Unassigned (U.S. National Phase of PCT/EP00/02545)

## Instructions as to Overpayment

Credit Account No. 12-1216.
Refund

Carol Larcher, Reg. No. 35,243 LEYDIG, WOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: September 28, 2001

ICOS Rec'd PCT/PTO 2 8 SEP 200T

Substitute f	for form	1449A/B/PTO
--------------	----------	-------------

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

	<u>(Use</u> as many	sheets as necessary)
Sheet	1	of

Complete if Known							
Application Number	Unassigned $\bigcap Q$	937908					
Filing Date	September 28, 2001	771700					
First Named Inventor	Ivo FEUSSNER						
Group Art Unit	Unassigned						
Examiner Name	Unassigned						
Attorney Docket Number	213721						

	U.S. PATENT DOCUMENTS							
		U.S. Patent Document						
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate		
			+					

	FOREIGN PATENT DOCUMENTS								
		Fo	reign Patent Docume	nt			Trans	slation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+	
				<u> </u>					
				<del> </del>					

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner	Doc. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		Translation	
Initials	No.	. I (book magazine journal serial symposium catalog etc.) date nage(s) volume-issue number(s) nublisher. I		No*+
	AA	FEUSSNER et al., "All three acyl moieties of trilinolein are efficiently oxygenated by recombinant His-tagged lipid body lipoxygenase in vitro," FEBS Letters, 431 (3), 433-436 (July 24, 1998)		
	AB	HORNUNG et al., "Conversion of cucumber linoleate 13-lipoxygenase to a 9-lipoxygenating species by site-directed mutagenesis," <i>PNAS USA</i> , 96 (7), 4192-4197 (March 30, 1999)		
	AC	PATENT ABSTRACTS OF JAPAN, 012 (338) (C-527) (September 12, 1988) & JP 63-098392 A (Agency of Ind. Science & Technology) (April 28, 1988)		
	AD	PATENT ABSTRACTS OF JAPAN, 014 (497) (C-0774) (October 30, 1990) & JP 02-207792 (Agency of Ind. Science & Technology) (August 17, 1990)		
	AE	PRIGGE et al., "Structure conservation in lipoxygenases: structural analysis of soybean lipoxygenase-1 and modeling of human lipoxygenases," <i>Proteins</i> , 24 (3), 275-291 (March, 1996)		
	AF	SLOANE et al., "Conversion of human 15-lipoxygenase to an efficient 12-lipoxygenase: the side-chain geometry of amino acids 417 and 418 determine positional specificity," Protein Engineering, 8 (3), 275-282 (March, 1995)		
	AG	STECZKO et al., "Conserved histidine residues in soybean lipoxygenase: functional consequences of their replacement," <i>Biochemistry</i> , 31 (16), 4053-4057 (April 28, 1992)		

Examiner Signature	Date Considered	

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).